Data Sheet (Cat.No.TMAY-02403)

Anti-S100P Antibody (1B730)

Product Details

Ig Type:	Rabbit IgG
Reactivity:	Human
Conjugation:	Unconjugated
Clone:	1B730
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of Human S100P expression on HeLa cells. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human S100P, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Application:	FCM
Recommended	FCM: 1:25-1:100

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human S100P Protein (TMPY-02216)
Antigen Species:	Human
Synonyms:	MIG9;S100 calcium binding protein P
Biology Area:	Calcium-binding Proteins and Related Molecules

Research Background

Protein S100-P, also known as Protein S100-E, S100 calcium-binding protein P, S100P and S100E, is a nucleus and cytoplasm protein that belongs to the S-100 family. S100P / S100E contains twoEF-hand domains. S100P protein regulates calcium signal transduction and mediates cytoskeletal interaction, protein phosphorylation and transcriptional control. S100P / S100E overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth. S100P / S100E may directly confer resistance to chemotherapy. S100P / S100E induction may be considered an important step in the initial stage of lung adenocarcinomas, whereas its downregulation in advanced stages seems to be important for tumour progression in which DNA methylation and/or feedback transcription processes play a critical role. S100P / S100E plays a major role in the aggressiveness of pancreatic cancer that is likely mediated by its ability to activate RAGE. Interference with S100P / S100E may provide a novel approach for treatment of pancreatic cancer. S100P / S100E could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481